Inhibitors of Transporters or Uptake of Monoaminergic Neurotransmitters

Background
One form of medical treatment for depression and neuropathic pain features a dual inhibitor called Cymbalta. This drug is manufactured and marketed by Eli Lilly. Researchers at Oregon State University have discovered a very efficient way of synthesizing Synosutine, which is comparable to Cymbalta in limited in vitro and in vivo assay. This drug could have powerful implications for treatment of depression and neuropathic pain.

Technology Description
This technology is a simple and efficient way for synthesizing Synosutine, a drug to be potentially used to treat depression and neuropathic pain.

Features & Benefits

• Much more efficient and quicker synthesis pathway than that for Cymbalta
• More balanced inhibition of serotonin and norepinephrine transporters makes Synosutine potentially a better treatment for neuropathic pain
• In vitro binding and in vivo microdialysis data available

Applications

• Treatment for depression and neuropathic pain

Status
Patented: US 8,772,330 B2